Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

QIAGEN Reports Results for Second Quarter and First Half of 2017

QIAGEN
Posted on: 29 Jul 17

VENLO, Netherlands, July 27, 2017 /PRNewswire/ --

 

Strong Q2 2017 results reaffirm QIAGEN on track to achieve full-year goals: 

Net sales $349.0 million (+4% actual); adjusted net sales $349.6 million (+5% actual, +7% CER vs. +5-6% CER guidance) 

EPS $0.06; adjusted EPS $0.25 ($0.25 CER), adjusted EPS excluding restructuring charge $0.30 ($0.30 CER vs. $0.28-0.29 CER guidance) 

H1 free cash flow of $91.6 million impacted by $30.8 million for restructuring 

Sample to Insight portfolio momentum with expansion of QuantiFERON latent TB test, Personalized Healthcare, NGS portfolio and QIAsymphony platform 

QIAGEN upgrades 2017 adjusted sales outlook after solid H1, now expects 7% CER growth; keeps adjusted EPS target before restructuring of $1.25-1.27 CER 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the second quarter and first half of 2017, delivering on goals for improvements in net sales and adjusted earnings.

"QIAGEN's performance for the second quarter of 2017 further strengthens our confidence in achieving our full-year goals for strong sales growth and a double-digit increase in adjusted earnings per share, as our differentiated portfolio of Sample to Insight molecular testing solutions gains momentum," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

Click here for the full press release

http://corporate.qiagen.com/newsroom/press-releases/2017/2017-07-27-q2results

www.twitter.com/qiagen 

www.facebook.com/QIAGEN 

Download the QIAGEN Investor Relations App

Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8

Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de

Contacts
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222

Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com
ir.qiagen.com

Public Relations:
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com
pr.qiagen.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 29/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.